Literature DB >> 22591029

Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft.

Nada Alachkar, Serena M Bagnasco, Robert A Montgomery.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22591029     DOI： 10.1111/j.1432-2277.2012.01497.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN： 0934-0874            Impact factor:   3.782


× No keyword cloud information.
  19 in total

1.  Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS.

Authors:  Roxanne Cofiell; Anjli Kukreja; Krystin Bedard; Yan Yan; Angela P Mickle; Masayo Ogawa; Camille L Bedrosian; Susan J Faas
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

Review 2.  An international consensus approach to the management of atypical hemolytic uremic syndrome in children.

Authors:  Chantal Loirat; Fadi Fakhouri; Gema Ariceta; Nesrin Besbas; Martin Bitzan; Anna Bjerre; Rosanna Coppo; Francesco Emma; Sally Johnson; Diana Karpman; Daniel Landau; Craig B Langman; Anne-Laure Lapeyraque; Christoph Licht; Carla Nester; Carmine Pecoraro; Magdalena Riedl; Nicole C A J van de Kar; Johan Van de Walle; Marina Vivarelli; Véronique Frémeaux-Bacchi
Journal:  Pediatr Nephrol       Date:  2015-04-11       Impact factor: 3.714

Review 3.  Novel immunosuppressive agents in kidney transplantation.

Authors:  Karen L Hardinger; Daniel C Brennan
Journal:  World J Transplant       Date:  2013-12-24

Review 4.  Hemolytic uremic syndrome.

Authors:  Caterina Mele; Giuseppe Remuzzi; Marina Noris
Journal:  Semin Immunopathol       Date:  2014-02-14       Impact factor: 9.623

5.  Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies.

Authors:  Christoph Licht; Larry A Greenbaum; Petra Muus; Sunil Babu; Camille L Bedrosian; David J Cohen; Yahsou Delmas; Kenneth Douglas; Richard R Furman; Osama A Gaber; Timothy Goodship; Maria Herthelius; Maryvonne Hourmant; Christophe M Legendre; Giuseppe Remuzzi; Neil Sheerin; Antonella Trivelli; Chantal Loirat
Journal:  Kidney Int       Date:  2015-02-04       Impact factor: 10.612

Review 6.  Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature.

Authors:  Sami Alasfar; Nada Alachkar
Journal:  Front Med (Lausanne)       Date:  2014-12-12

Review 7.  Can eculizumab be discontinued in aHUS?: Case report and review of the literature.

Authors:  Tuncay Sahutoglu; Taner Basturk; Tamer Sakaci; Yener Koc; Elbis Ahbap; Mustafa Sevinc; Ekrem Kara; Cuneyt Akgol; Feyza Bayraktar Caglayan; Abdulkadir Unsal; Mohamed R Daha
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

Review 8.  Complement therapy in atypical haemolytic uraemic syndrome (aHUS).

Authors:  Edwin K S Wong; Tim H J Goodship; David Kavanagh
Journal:  Mol Immunol       Date:  2013-06-28       Impact factor: 4.174

Review 9.  Late and chronic antibody-mediated rejection: main barrier to long term graft survival.

Authors:  Qiquan Sun; Yang Yang
Journal:  Clin Dev Immunol       Date:  2013-10-08

Review 10.  Critical appraisal of eculizumab for atypical hemolytic uremic syndrome.

Authors:  Lilian M Pereira Palma; Craig B Langman
Journal:  J Blood Med       Date:  2016-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.